Search

Aim Although Graves’ disease (GD) is common in endocrine practices worldwide, global differences in diagnosis and management remain. We sought to assess the current practices for GD in countries across Asia and the Pacific (APAC), and to compare these with previously published surveys from North-America and Europe. Methods A web-based survey on GD management was conducted on a pool of practicing physicians. Responses from 542 eligible physicians were received and subsequently analysed and compared to outcomes from other, similar surveys. Results During initial work-up, majority of respondents would request thyroid-stimulating hormone (TSH; 73%) and free thyroxine assays (75%), as well as TSH-receptor autoantibodies (68%). Thyroid ultrasound would be requested by about half of respondents (53%), while the use of nuclear medicine scans was very limited. The preferred first-line treatment was antithyroid drug (ATD) therapy (79%) with methimazole (MMI) or carbimazole (CBZ), followed by radioiodine (RAI; 19%) and surgery (2%). In case of surgery, one-third of respondents would opt for a subtotal rather than a total thyroidectomy. In case of mild Graves orbitopathy (GO), ATDs (67%) remained the preferred treatment, but a larger proportion would prefer surgery (20%). For a patient with a pregnancy (wish), the overall preferred treatment pattern remained unchanged, although propylthiouracil (PTU) became the preferred ATD-agent during the first trimester. While on most issues choices of the physicians from APAC fell between European and American practices, marked differences were noted in the relatively infrequent usage of nuclear medicine scans and the overall higher concomitant use of a ATDs and β-blockers and adjunctive ATD-treatment during RAI. Conclusion Although regional differences regarding the diagnosis and management of GD are apparent in this first pan-Asia-Pacific survey, the overall approach to the management of this disease in APAC to generally fall between the trends appreciated in the American and European cohorts.

Although Graves' disease (GD) is common in endocrine practices worldwide, global differences in diagnosis and management remain. We sought to assess the current practices for GD in countries across Asia and the Pacific (APAC), and to compare these with previously published surveys from North America and Europe.A web-based survey on GD management was conducted on practicing clinicians. Responses from 542 clinicians were received and subsequently analysed and compared to outcomes from similar surveys from other regions.A total of 542 respondents participated in the survey, 515 (95%) of whom completed all sections. Of these, 86% were medical specialists, 11% surgeons, and 3% nuclear medicine physicians. In addition to serum thyroid-stimulating hormone (TSH) and free thyroxine assays, most respondents would request TSH-receptor autoantibody (TRAb) measurement (68%) during initial work-up. Thyroid ultrasound is requested by about half of respondents (53%), while the use of nuclear medicine scans is limited. The preferred first-line treatment is anti-thyroid drug (ATD) therapy (79%) with methimazole (MMI) or carbimazole (CBZ), followed by radioiodine (RAI; 19%) and surgery (2%). In case of surgery, one-third of respondents would opt for a subtotal rather than a total thyroidectomy. In case of mild Graves orbitopathy (GO), ATDs (67%) remains the preferred treatment, but a larger proportion of clinicians prefer surgery (20%). For a patient with intention to conceive, the preferred treatment pattern remained unchanged, although propylthiouracil (PTU) became the preferred ATD-agent during the first trimester. In comparison to European and American practices, marked differences were noted in the relatively infrequent usage of nuclear medicine scans and the overall higher use of a ATDs and β-blockers and adjunctive ATD-treatment during RAI in the APAC-group.Although regional differences regarding the diagnosis and management of GD are apparent in this first pan-Asia-Pacific survey, this study reveals the overall approach to the management of this disease in Asia-Pacific generally tends to fall between the trends appreciated in the American and European cohorts.

[No abstract available]

No abstract available